Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Anaxagoras who wrote (1077)	8/3/1998 8:53:00 PM
From: John L.	Respond to of 1432

I doubt that anything is going to happen until the FDA speaks, hopefully soon. The posts on this and Yahoo are extremist either for or against BTIM, there is little useful information coming out. I hope it is because the company can not promote it's product while in the FDA process. Mostly I read cheerleading and naysaying about BTIM on the message boards, few solid facts.

To: Anaxagoras who wrote (1077)	8/4/1998 9:06:00 PM
From: mesaone	Read Replies (1) \| Respond to of 1432

The correlation between albumin and Hextend is that both albumin solutions (e.g. albumin in normal saline) and other solutions used to replace lost blood volume ("plasma expanders" such as Hextend) are used to treat the same medical conditions (shock, hypovolemia). Therefore if albumin is suddenly found to be unsuitable for this application (which is the conclusion of the authors of the BMJ paper) then the other solutions must be used instead. And since the generic hydroxyethyl starch in normal saline solution (Hespan) is known to cause bleeding problems, this means that Hextend, once approved by the FDA, will be the leading candidate to replace albumin based solutions. Note also that if the problem with the existing albumin solutions is that they are albumin in normal saline (as opposed to albumin in a physiologically balanced electrolyte solution) then the problems causing addtional deaths with albumin may actually be caused by the elecytrolyte imbalance of the carrier solution, and not the albumin proper. If this is the case, then any attempt to reformulate albumin solutions to correct these problems will interfere with BioTime's patents, which cover not only solutions which use hydroxyethyl starch (HES) as the oncotic agent but also solutions containing albumin. Additionally, some think that HES may be better than albumin when treating individuals with damaged, "leaky" capillaries since the HES molecules are physically larger than the albumin molecules and so may help plug up and seal small leaks in the capillary walls, reducing edema. In any case, it is clear that administering today's albumin based solutions caused additional deaths in the studies reviewed in the BMJ paper, and that doctors will be looking for alternatives such as Hextend to use instead. This increases the natural market for Hextend.